Circulating Tumor Cells: Finding Rare Events for A Huge Knowledge of Cancer Dissemination

The analysis of circulating tumor cells (CTCs) as a real-time liquid biopsy approach can be used to obtain new insights into metastasis biology, and as companion diagnostics to improve the stratification of therapies and to obtain insights into the therapy-induced selection of cancer cells. In this...

Full description

Saved in:
Bibliographic Details
:
Year of Publication:2020
Language:English
Physical Description:1 electronic resource (366 p.)
Tags: Add Tag
No Tags, Be the first to tag this record!
LEADER 05131nam-a2201513z--4500
001 993548482504498
005 20231214132836.0
006 m o d
007 cr|mn|---annan
008 202102s2020 xx |||||o ||| 0|eng d
020 |a 3-03928-699-4 
035 |a (CKB)4100000011302224 
035 |a (oapen)https://directory.doabooks.org/handle/20.500.12854/43261 
035 |a (EXLCZ)994100000011302224 
041 0 |a eng 
100 1 |a Alix-Panabieres, Catherine  |4 auth 
245 1 0 |a Circulating Tumor Cells: Finding Rare Events for A Huge Knowledge of Cancer Dissemination 
246 |a Circulating Tumor Cells 
260 |b MDPI - Multidisciplinary Digital Publishing Institute  |c 2020 
300 |a 1 electronic resource (366 p.) 
336 |a text  |b txt  |2 rdacontent 
337 |a computer  |b c  |2 rdamedia 
338 |a online resource  |b cr  |2 rdacarrier 
520 |a The analysis of circulating tumor cells (CTCs) as a real-time liquid biopsy approach can be used to obtain new insights into metastasis biology, and as companion diagnostics to improve the stratification of therapies and to obtain insights into the therapy-induced selection of cancer cells. In this book, we will cover all the different facets of CTCs to assemble a huge corpus of knowledge on cancer dissemination: technologies for their enrichment, detection, and characterization; their analysis at the single-cell level; their journey as CTC microemboli; their clinical relevance; their biology with the epithelial-to-mesenchymal transition (EMT); their stem-cell properties; their potential to initiate metastasis at distant sites; their ex vivo expansion; and their escape from the immune system. 
546 |a English 
653 |a FOLFIRINOX 
653 |a immunofluorescence imaging 
653 |a AR-V7 
653 |a circulating tumour cells 
653 |a chemoradioresistance 
653 |a CTC-based treatment decisions 
653 |a rVAR2 
653 |a immunophenotyping 
653 |a immune system 
653 |a CellSearch® 
653 |a flow cytometry 
653 |a clinical trials 
653 |a circulating tumor DNA 
653 |a synaptophysin 
653 |a stem cells 
653 |a colorectal cancer 
653 |a melanoma 
653 |a CTC biology 
653 |a platelets 
653 |a AR 
653 |a CTC capture technology 
653 |a castration resistant prostate cancer (CRPC) 
653 |a PD-L1 expression 
653 |a rovalpituzumab tesirine 
653 |a HMB-45 
653 |a thymidylate synthase 
653 |a ctDNA 
653 |a tumor cell dissemination 
653 |a solid cancers 
653 |a metastasis 
653 |a locally advanced rectal cancer 
653 |a miRNA 
653 |a epithelial-to-mesenchymal transition (EMT) 
653 |a NSCLC 
653 |a tumor biomarkers 
653 |a tumor stem cells 
653 |a circulating tumor cells 
653 |a major histocompatibility complex class I (MHCI) 
653 |a bone marrow 
653 |a heterogeneity 
653 |a cerebrospinal liquid biopsy 
653 |a fish 
653 |a glioma 
653 |a in vivo flow cytometry 
653 |a colorectal surgery 
653 |a CellSearch 
653 |a single-cell analysis 
653 |a disseminated tumor cells 
653 |a EasyCount slides 
653 |a microsatellite instability 
653 |a circulating plasma cells 
653 |a circulating leukemia cells 
653 |a ARV7 
653 |a SLUG 
653 |a androgen receptor 
653 |a metastatic colorectal cancer 
653 |a leukocyte-derived extracellular vesicles 
653 |a prostate cancer (PCa) 
653 |a neutrophils 
653 |a liquid biopsy 
653 |a enzalutamide 
653 |a CD133 
653 |a enrichment and detection technologies 
653 |a biomarkers 
653 |a immune checkpoint inhibitors 
653 |a biomarker 
653 |a RAD23B 
653 |a microbiome 
653 |a integrin B1 
653 |a ACCEPT 
653 |a emboli 
653 |a small-cell lung carcinoma 
653 |a EPISPOT 
653 |a microfluidics 
653 |a early breast cancer 
653 |a circulating tumor cells (CTC) 
653 |a tumor-initiating cells (TICs) 
653 |a immunomodulation 
653 |a xenograft models 
653 |a CTC-derived xenografts 
653 |a malaria 
653 |a circulating tumor cells (CTCs) 
653 |a clinical utility 
653 |a exosomes 
653 |a liquid surgery 
653 |a ctRNA 
653 |a CTCs 
653 |a epithelial-mesenchymal transition 
653 |a targeted therapy 
653 |a hematological cells 
653 |a gene expression analysis 
653 |a hepatocellular carcinoma (HCC) 
653 |a breast cancer 
653 |a EpCAM enrichment 
653 |a prostate cancer 
653 |a CTC 
653 |a abiraterone 
653 |a fibronectin 
653 |a CTC-derived ex vivo models 
653 |a CTMat 
653 |a chromogranin A 
653 |a CTM 
653 |a exosome 
776 |z 3-03928-698-6 
906 |a BOOK 
ADM |b 2023-12-15 05:33:22 Europe/Vienna  |f system  |c marc21  |a 2020-06-20 22:16:43 Europe/Vienna  |g false 
AVE |i DOAB Directory of Open Access Books  |P DOAB Directory of Open Access Books  |x https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&portfolio_pid=5338827220004498&Force_direct=true  |Z 5338827220004498  |b Available  |8 5338827220004498